期刊文献+

博尔宁胶囊联合FOLFOX4方案与单纯FOLFOX4方案治疗结肠癌的临床疗效对比 被引量:5

下载PDF
导出
摘要 目的在结肠癌治疗中应用FOLFOX4方案联合博尔宁胶囊与单纯应用FOLFOX4方案的临床效果。方法 68例结肠癌患者,根据治疗方法不同分为联合组(38例)和单用组(30例)。联合组接受FOLFOX4方案联合博尔宁胶囊治疗,单用组单纯应用FOLFOX4方案治疗。观察两组患者近期疗效、体质量及不良反应发生情况。结果联合组治疗总有效率为63.16%,高于单用组的43.33%,差异具有统计学意义(P<0.05)。治疗后联合组患者体质量明显高于单用组(P<0.05)。联合组不同治疗周期白细胞(WBC)Ⅱ度以上血液毒性事件发生率低于单用组(P<0.05)。联合组恶心、呕吐、神经毒性、腹泻及皮疹等不良反应发生率均低于单用组(P<0.05)。结论在结肠癌治疗中,在FOLFOX4方案基础上联合应用博尔宁胶囊,可有效提高治疗效果,减少不良反应发生,减轻患者治疗痛苦,值得推广。
出处 《中国现代药物应用》 2016年第16期121-123,共3页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献2

二级参考文献26

  • 1Camp E R,Summy J,Bauer T W,et aI.Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor[J]. Clin Cancer Ees,2005,11(1):397--405.
  • 2Ng M,Ounningham D.Oetuximab(Erbitux)-an emerging targeted therapy for epidermal growth factor receptor-expressing tumours[J].Int J Olin Pract,2004,58(10):970-976.
  • 3Bokemeyer C,Bondarenko I,Makhson A,et al. Oetuximab plus 5-FU/FA/oxalip latin (FOLFOX4) versus FOLFOX4 in the first-line treatment of metAstAtic co]orectal cancer (mCRC):OPUS,a randomized phage II study[J].J Olin Oncol,2007,25(18Suppl).4035-4052.
  • 4Tabernero J,Van Cutaem E,Diaz Eubio E,et al.Phase II trial of cetuximab in combination with fluorouracil,leucovorin,and oxalip latin in the first line treatment ofmetastatic colorectal cancer[J].J Clin Oncol, 2007,25(33): 5225-5252.
  • 5Vincenzi B,Santini D Tonini D.New issues on cetuximab mechanism of action in epfdermal growth factor receptor-negative colorectal cancer:the robe of vascular endothelial growth factor[J].J Clin Oncol,2006 24(12):1957-1958.
  • 6Cunningham P,Humblet Y,Siena S,et al.Oetuximab monotherapy and cetuximab pJus irinotecan in irinotecan refractory metastatic colorectal cancer[J].N Engl J Med,2004,351(4):337--345.
  • 7Tsuchihashi Z,Hanna N,Janne P A.Eesponsiveness to cetuximab without mutations in EOFE[J].N Engl J Med,2005,353(2):208-209.
  • 8Skvortsov S,Sarg B,Loeffler-Ragg J,et aI.Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to Cetuximab antibody treatment[J].Mol Cancer Ther,2004,3(2):1551-1558.
  • 9Foiprecht G,Lutz M P,Schiffski P,et al.Cetuximab and irinotecan/5--fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma[J]. Ann Oncol, 2006, 17(3): 450-456.
  • 10Saltz L B,Kies J,Abbruzzese N,et al. The presence and intensity of the cetuximab induced ache like rash predicts survival in studies across multiple malignancies[J].Proc Am Soc Clin Oncol,2003,22:204.

共引文献26

同被引文献62

引证文献5

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部